MedPAC Member Suggests Expanding Insulin Cap Demo To Other Drugs

By John Wilkerson / January 18, 2022 at 2:35 PM

The Medicare demonstration that caps beneficiaries’ monthly insulin costs might be a model to consider for other highly rebated drugs that treat chronic conditions, if Congress fails to overhaul Part D, a congressional Medicare adviser said Friday (Jan. 14).



Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.